Gw Pharmaceuticals Plc Revenue Growth Rates (GWPH), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Gw Pharmaceuticals Plc  (NASDAQ: GWPH)
 

GWPH's Revenue Growth by Quarter and Year

Gw Pharmaceuticals Plc's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

GWPH Revenue (in millions $) FY 2021 FY 2020 FY 2019 FY 2018
4th Quarter December -
3rd Quarter September -
2nd Quarter June -
1st Quarter March 152.47
FY 152.47





GWPH Revenue first quarter 2021 Y/Y Growth Comment
Gw Pharmaceuticals Plc reported Revenue improvement of 26.39% year on year in the first quarter 2021, to $ 152.47 millions, this is lower than Gw Pharmaceuticals Plc's recent average Revenue rise of 88.2%.
This represents worst decline in recent Company history.

Looking into first quarter 2021 results within Major Pharmaceutical Preparations industry 94 other companies have achieved higher Revenue growth. While Gw Pharmaceuticals Plc' s Revenue rise of 26.39% ranks overall at the positon no. 1161 in the first quarter 2021.


GWPH Revenue ( Y/Y Growth %) 2021
 2020 2019 2018
4th Quarter December - 35.88 % 1540.3 % 66.67 %
3rd Quarter September - 50.65 % 3659.09 % -1.22 %
2nd Quarter June - 68.38 % 2096.34 % 18.84 %
1st Quarter March 26.39 % 207.34 % 1191.12 % 120.29 %
FY   - 69.33 % 1923 % -

Financial Statements
Gw Pharmaceuticals Plc's first quarter 2021 Revenue $ 152.47 millions GWPH's Income Statement
Gw Pharmaceuticals Plc's first quarter 2020 Revenue $ 120.63 millions Quarterly GWPH's Income Statement


GWPH Revenue (Quarter on Quarter Growth %)

 2021
 2020 2019 2018
4th Quarter December - 8.15 % 19.91 % 174.79 %
3rd Quarter September - 12.98 % 26.28 % -26.22 %
2nd Quarter June - 0.56 % 83.54 % 7.89 %
1st Quarter March 2.86 % 10.59 % 490.23 % -23.81 %
FY (Year on Year)   - 69.33 % 1923 % -


Back to GWPH Growth rate Comparisons >> Back to GWPH Growth rate Comparisons >>


Revenue first quarter 2021 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #95
Healthcare Sector #211
Overall #1161

Revenue Y/Y Growth Statistics
High Average Low
207.37 % 88.2 % 26.39 %
(Mar 31 2020)   (Mar 31 2021)
Revenue first quarter 2021 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #95
Healthcare Sector #211
Overall #1161
Revenue Y/Y Growth Statistics
High Average Low
207.37 % 88.2 % 26.39 %
(Mar 31 2020)   (Mar 31 2021)

Revenue by Quarter for the Fiscal Years 2018, 2019, 2020, 2021

Gw Pharmaceuticals Plc's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
489.83 % 53.36 % -32.1 %
(Mar 31 2019)  


GWPH's I. Quarter Q/Q Revenue Comment
Gw Pharmaceuticals Plc achieved in the I. Quarter 2021 below company average Revenue growth of 2.86% quarter on quarter, to $ 152.47 millions.

Within Major Pharmaceutical Preparations industry 110 other companies have achieved higher Revenue quarter on quarter growth. While Gw Pharmaceuticals Plc's Revenue growth quarter on quarter, overall rank is 2039.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #111
Healthcare Sector #271
Overall #2039
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #111
Healthcare Sector #271
Overall #2039
Revenue Q/Q Growth Statistics
High Average Low
489.83 % 53.36 % -32.1 %
(Mar 31 2019)  


GWPH's I. Quarter Q/Q Revenue Comment
Gw Pharmaceuticals Plc achieved in the I. Quarter 2021 below company average Revenue growth of 2.86% quarter on quarter, to $ 152.47 millions.

Within Major Pharmaceutical Preparations industry 110 other companies have achieved higher Revenue quarter on quarter growth. While Gw Pharmaceuticals Plc's Revenue growth quarter on quarter, overall rank is 2039.


Gw Pharmaceuticals Plc's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Mar 31 2021)		 12 Months Ending
(Dec 31 2020)		 12 Months Ending
(Sep 30 2020)		 12 Months Ending
(Jun 30 2020)		 12 Months Ending
(Mar 31 2020)
Cumulative Revenue 12 Months Ending $ 559.04 $ 527.21 $ 488.06 $ 441.98 $ 392.72
Y / Y Revenue Growth (TTM) 42.35 % 69.34 % 133.62 % 267.22 % 661.01 %
Year on Year Revenue Growth Overall Ranking # 2738 # 1799 # 0 # 0 # 0
Seqeuential Revenue Change (TTM) 6.04 % 8.02 % 10.43 % 12.54 % 26.14 %
Seq. Revenue Growth (TTM) Overall Ranking # 675 # 3732 # 477 # 264 # 672


Cumulative Revenue growth Comment
Assuming the Gw Pharmaceuticals Plc's fiscal year would have ended in Mar 31 2021, Gw Pharmaceuticals Plc would have reprted above average annual Revenue growth of 42.35% year on year, of $ 559 millions.
This marks a slow-down of the companys growth trends and from the 69.34% increase in Dec 31 2020.

In the Healthcare sector 397 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1799 to 2738.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 78
Healthcare Sector # 398
Overall # 2738

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
 -6.31 %
-12.62 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 78
Sector # 161
S&P 500 # 675
Cumulative Revenue growth Comment
Assuming the Gw Pharmaceuticals Plc's fiscal year would have ended in Mar 31 2021, Gw Pharmaceuticals Plc would have reprted above average annual Revenue growth of 42.35% year on year, of $ 559 millions.
This marks a slow-down of the companys growth trends and from the 69.34% increase in Dec 31 2020.

In the Healthcare sector 397 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 1799 to 2738.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 78
Healthcare Sector # 398
Overall # 2738

Revenue TTM Y/Y Growth Statistics
High Average Low
0 %
-6.31 %
-12.62 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 78
Sector # 161
S&P 500 # 675




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
GWPH's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue increase for the quarter ending Mar 31 2021 within Healthcare SectorY/Y Change %Revenue for the quarter ending Mar 31 2021
Dyadic International Inc 46.02%$ 46.024 millions
Rigel Pharmaceuticals Inc45.30%$ 45.295 millions
Tandem Diabetes Care Inc 44.02%$ 44.024 millions
Butterfly Network Inc 43.52%$ 43.518 millions
Hookipa Pharma inc 43.43%$ 43.425 millions
Jaguar Health Inc 42.81%$ 42.808 millions
Elite Health Systems Inc 42.03%$ 42.035 millions
Agilon Health Inc 41.94%$ 41.937 millions
Arbutus Biopharma Corp41.72%$ 41.717 millions
Intelgenx Technologies Corp 41.58%$ 41.584 millions
Seagen Inc 41.56%$ 41.562 millions
Resmed Inc 40.27%$ 40.275 millions
Dicerna Pharmaceuticals Inc 39.89%$ 39.894 millions
Semler Scientific inc 39.80%$ 39.799 millions
Arrowhead Pharmaceuticals Inc 39.45%$ 39.450 millions
Scienture Holdings Inc 38.57%$ 38.574 millions
Biolife Solutions Inc 38.52%$ 38.522 millions
Catalent Inc 38.48%$ 38.483 millions
Regeneron Pharmaceuticals Inc 38.32%$ 38.316 millions
Pro dex Inc 37.98%$ 37.976 millions
Supernus Pharmaceuticals inc 37.86%$ 37.858 millions
Genedx Holdings Corp 37.61%$ 37.608 millions
Sientra Inc 37.23%$ 37.231 millions
Signify Health Inc 36.67%$ 36.674 millions
West Pharmaceutical Services Inc 36.46%$ 36.460 millions
Abbott Laboratories35.34%$ 35.335 millions
Phenomex Inc 35.20%$ 35.201 millions
Capforce Inc 34.49%$ 34.490 millions
Veru Inc 34.17%$ 34.168 millions
China Pharma Holdings Inc33.70%$ 33.698 millions


About Gw Pharmaceuticals Plc Revenue Growth Rates (GWPH), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: the company’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.